Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has received an average recommendation of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $67.75.
A number of equities analysts have recently issued reports on the company. ValuEngine downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Zacks Investment Research downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BMO Capital Markets increased their target price on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Jefferies Group LLC reissued a “buy” rating and set a $52.00 target price on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $41.00 target price on shares of Five Prime Therapeutics in a research note on Wednesday, October 25th.
TRADEMARK VIOLATION NOTICE: “Five Prime Therapeutics, Inc. (FPRX) Given Average Recommendation of “Hold” by Brokerages” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/11/19/five-prime-therapeutics-inc-fprx-given-average-recommendation-of-hold-by-brokerages.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning grew its holdings in shares of Five Prime Therapeutics by 0.8% in the 2nd quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Five Prime Therapeutics during the 3rd quarter valued at $223,000. Legal & General Group Plc grew its holdings in Five Prime Therapeutics by 3.1% during the 2nd quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 287 shares during the last quarter. Tudor Investment Corp ET AL grew its holdings in Five Prime Therapeutics by 56.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,033 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 2,910 shares during the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in Five Prime Therapeutics during the 2nd quarter valued at $331,000. Institutional investors and hedge funds own 81.90% of the company’s stock.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down $0.20 during mid-day trading on Friday, hitting $25.56. The stock had a trading volume of 407,092 shares, compared to its average volume of 916,058. Five Prime Therapeutics has a fifty-two week low of $21.41 and a fifty-two week high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the company posted ($0.72) earnings per share. research analysts anticipate that Five Prime Therapeutics will post -5.56 earnings per share for the current year.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.